NVUS News and Press, Novus Therapeutics Inc.

Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody ...

Gainers: Ocugen (OCGN) +263%, Jaguar Health (JAGX) +108%, Acasti Pharma (ACST) +61%, Scopus BioPharma (SCPS) +43%, Ekso Bionics Holdings (EKSO) +21%.Losers: Cellectar Biosciences (CLRB) -31%, CRH Medical (CRHM) -23%, CNS Pharmaceuticals (...

IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those l...

Former Chief Development and Chief Operating Officer of MyoKardia, Inc. brings extensive clinical development expertise as Novus prepares to conduct up to four Phase 2 clinical trials Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharma...

Novus Therapeutics, Inc. (NVUS) Q3 2020 Earnings Conference Call November 16, 2020 04:30 PM ET Company Participants Jon Kuwahara - Senior Vice President of Finance David-Alexandre Gros - Chief Executive Officer Steve Perrin - President & Chief Scientific Officer Conference Call Participan...

Novus Therapeutics (NVUS): Q3 GAAP EPS of -$5.51 misses by $3.76.The company had $114.5M in cash and equivalents as of September 30, 2020.Press Release For further details see: Novus Therapeutics EPS misses by $3.76

Company to host conference call and webcast at 4:30pm ET today Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transp...

Management to host a conference call and webcast at 4:30 PM ET on that day Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cel...

The first subject has been enrolled in Novus Therapeutics' (NVUS) Phase 2a clinical trial evaluating anti-CD40L antibody, AT-1501 in adults with amyotrophic lateral sclerosis ((ALS)), a neurodegenerative neuromuscular disease resulting in the progressive loss of motor neurons that contro...

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today annou...